Holdener E E, Osterwalder J, Senn H J, Enderlin F, Gloor F
Schweiz Med Wochenschr. 1982 Dec 4;112(49):1800-4.
Second malignancies (SM) represent one of the potential hazards of modern cancer treatment and especially of radio- and chemotherapy after surgery for breast cancer. For this reason, regional tumor registry data (1960-1975) on 1985 breast cancer patients were analyzed for SM in the retrospective part of our study. These data were compared with the prospective part of the study in which 241 patients were randomly assigned to either mastectomy or mastectomy and chemoimmunotherapy (CT + IT). In the retrospective part of the study, SM were observed in 83 cases (4.2%), 49% of which were SM of the contralateral breast. Most frequent extramammary SM were of gastrointestinal (25%), gynecologic (8%) and cerebral (5%) origin. Leukemias were found in 4% of all SM. Median time interval to SM was 5 years and 1 month. Within 5, 10 and 15 years after mastectomy 60%, 85% and 95% of SM were observed respectively. Median survival of patients with SM was 6 1/2 years. In the prospective part of the study, SM were observed in 9 cases (3.7%), 4.1% in the surgical control group and 3.4% in the adjuvant CT + IT group with a median observation time of 6 years post mastectomy. These data are compared to other current adjuvant breast trials and do not indicate as of now an increase in SM under present adjuvant therapy.
第二原发恶性肿瘤(SM)是现代癌症治疗尤其是乳腺癌手术后放疗和化疗的潜在危害之一。因此,在我们研究的回顾性部分,分析了1985例乳腺癌患者的区域肿瘤登记数据(1960 - 1975年)以了解第二原发恶性肿瘤情况。这些数据与研究的前瞻性部分进行了比较,在前瞻性部分,241例患者被随机分配接受乳房切除术或乳房切除术加化学免疫疗法(CT + IT)。在研究的回顾性部分,观察到83例(4.2%)第二原发恶性肿瘤,其中49%是对侧乳房的第二原发恶性肿瘤。最常见的乳腺外第二原发恶性肿瘤起源于胃肠道(25%)、妇科(8%)和脑部(5%)。在所有第二原发恶性肿瘤中,白血病占4%。出现第二原发恶性肿瘤的中位时间间隔为5年零1个月。乳房切除术后5年、10年和15年内分别观察到60%、85%和95%的第二原发恶性肿瘤。第二原发恶性肿瘤患者的中位生存期为6.5年。在研究的前瞻性部分,观察到9例(3.7%)第二原发恶性肿瘤,手术对照组为4.1%,辅助CT + IT组为3.4%,乳房切除术后中位观察时间为6年。这些数据与其他当前的辅助性乳腺癌试验进行了比较,目前并未表明当前辅助治疗下第二原发恶性肿瘤的发生率增加。